Hoseini Seyed Mousalreza, Anushiravani Majid, Mojahedi Mohammad Javad, Hami Maryam, Zibaee Saeid, Rakhshandeh Hassan, Taghipour Ali, Nikakhtar Zahra, Eshraghi Hamid, Tavassoli Amir Parviz
Department of Gastroenterology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Persian Medicine, School of Persian and Complementary Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Avicenna J Phytomed. 2020 Mar-Apr;10(2):170-180.
This study was designed to investigate the effect of camel milk and Tarangabin (manna of ) combination therapy in addition to conventional treatments in patients with chronic kidney disease (CKD).
Forty-four patients of 15 to 70 years old, with CKD due to hypertension or diabetes, and estimated glomerular filtration rate (eGFR) of 15-60 ml/min per 1.73 m, were enrolled in this trial. The patients were randomized to receive either 400 cc of camel milk with 10 cc of Tarangabin syrup orally in two divided daily doses for 3 months plus conventional therapy or conventional therapy alone. The conventional treatment included diabetes medications and angiotensin converting enzyme inhibitors or angiotensin receptor blockers.
The baseline characteristics of patients were similar in the two groups. Serum levels of creatinine (p=0.01), blood levels of urea nitrogen (p=0.0001), triglyceride (p=0.02), and potassium (p=0.05), and diastolic blood pressure (p=0.0001) decreased, while eGFR (p=0.001) improved in intervention group significantly.
It seems that the therapeutic protocol used in this study can improve renal function in patients with CKD through regulating glucose and anti-inflammatory, laxative, and immunostimulatory properties.
本研究旨在探讨除传统治疗外,骆驼奶与塔兰加宾(甘露)联合治疗对慢性肾脏病(CKD)患者的影响。
本试验纳入了44例年龄在15至70岁之间、因高血压或糖尿病导致CKD且估算肾小球滤过率(eGFR)为每1.73平方米15 - 60毫升/分钟的患者。患者被随机分为两组,一组每天分两次口服400毫升骆驼奶加10毫升塔兰加宾糖浆,持续3个月,同时接受传统治疗;另一组仅接受传统治疗。传统治疗包括糖尿病药物以及血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂。
两组患者的基线特征相似。干预组患者的血清肌酐水平(p = 0.01)、血尿素氮水平(p = 0.0001)、甘油三酯水平(p = 0.02)、钾水平(p = 0.05)以及舒张压(p = 0.0001)均下降,而eGFR(p = 0.001)显著改善。
本研究中使用的治疗方案似乎可通过调节血糖以及抗炎、通便和免疫刺激特性来改善CKD患者的肾功能。